JPMorgan Upgrades Biogen (BIIB) to Overweight
Tweet Send to a Friend
JPMorgan analyst Chris Schott upgraded Biogen (NASDAQ: BIIB) from Neutral to Overweight with a price target of $300.00 (from $210.00).The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




